‘Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress’, the webinar will explore recent breakthroughs and ongoing challenges in the ALS landscape, including the biological drivers of disease and how advances in drug development are improving the patient experience, while underscoring where significant gaps remain. The discussion will highlight Coya’s novel immunotherapy approach for treating ALS, including the scientific rationale behind its combination therapy COYA 302 and will feature an overview of the Company’s ALSTARS Phase 2 clinical trial, including its design and enrollment information.
Fred Grossman, D.O., FAPA, President and Chief Medical Officer of Coya Therapeutics, will serve as the moderator for the webinar. He will be joined by the following participants:
- Stanley Appel, M.D. – Chairman, Scientific Advisory Board, Coya Therapeutics; Professor of Neurology, Houston Methodist
- James Berry, M.D., MPH – Director, Massachusetts General Hospital Multidisciplinary ALS Clinic